Return to search results
Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES
The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R1 and R2 are each independently hydrogen or C1-C4 alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[ "009:25" ] |
| contactPoint |
{ "fn": "NIH/NCBI Data Team", "@type": "vcard:Contact", "hasEmail": "mailto:info@ncbi.nlm.nih.gov" } |
| description | The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are each independently hydrogen or C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Official Data Source", "mediaType": "text/html", "description": "Access the complete Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES on the official website.", "downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400268-T1" } ] |
| identifier | https://healthdata.gov/api/views/daks-4rnw |
| issued | 2025-09-05 |
| keyword |
[ "chemistry", "innovation", "patent", "pubchem", "research" ] |
| landingPage | https://healthdata.gov/d/daks-4rnw |
| modified | 2025-09-06 |
| programCode |
[ "009:066" ] |
| publisher |
{ "name": "National Center for Biotechnology Information (NCBI)", "@type": "org:Organization" } |
| theme |
[ "NIH" ] |
| title | Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES |
